BioCardia (BCDA) director Blank received 12,000 Stock Option (right to buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Andrew Scott Blank (director at BioCardia Inc., BCDA) reported that they received 12,000 Stock Option (right to buy) on Dec 8, 2025.
- Reporting person
- Blank Andrew Scott
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | Grant or award (A) | Stock Option (right to buy)On 12,000 Common Stock1 | +12,000 | - | - | 15,313 direct |
Holdings before and after
- Stock Option (right to buy): 3,313 to 15,313 direct
Footnotes from the filing
- 1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Blank report in this BCDA Form 4?
Andrew Scott Blank (director at BioCardia Inc., BCDA) reported that they received 12,000 Stock Option (right to buy) on Dec 8, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for BCDA
Across the 7 sessions after earlier BCDA headlines, the stock closed higher 2 times and lower 5 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BCDA | SPY |
|---|---|---|---|
| Dec 3, 2025 | BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno | +3.6% | +0.3% |
| Dec 1, 2025 | BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress | -4.1% | -0.5% |
| Nov 24, 2025 | BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality | +0.7% | +1.5% |
| Nov 13, 2025 | BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results | -3.1% | -1.7% |
| Nov 10, 2025 | BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial | -0.8% | +1.6% |
| Nov 6, 2025 | BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 | -3.0% | -1.1% |
Earlier insider filings at BCDA
- Dec 11, 2025SEC Form 4 filed by Director Stertzer Simon H
- Dec 11, 2025SEC Form 4 filed by Director Facteau Bill
- Dec 11, 2025SEC Form 4 filed by Director Slosman Marvin
- Sep 23, 2025Director Stertzer Simon H bought $498,000 worth of shares (398,400 units at $1.25) (SEC Form 4)
- Sep 23, 2025Director Blank Andrew Scott bought $360,000 worth of shares (288,000 units at $1.25) (SEC Form 4)
Quantisnow market dataNASDAQ
BCDA
BioCardia Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for BCDA
Full BCDA profile on Quantisnow Follow BCDA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time